{"id":"16mg-kb","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"However, the exact mechanism of action of KB is not well understood at this time.","oneSentence":"KB is a small molecule drug that targets the mechanism of action of the drug.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:19:08.365Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 2 clinical trials for KB are ongoing, but the specific indication is not publicly disclosed."}]},"trialDetails":[{"nctId":"NCT04803955","phase":"PHASE2","title":"Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients","status":"RECRUITING","sponsor":"Tianjin Chasesun Pharmaceutical Co., LTD","startDate":"2021-05-15","conditions":"Sepsis","enrollment":424}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"16mg，KB","genericName":"16mg，KB","companyName":"Tianjin Chasesun Pharmaceutical Co., LTD","companyId":"tianjin-chasesun-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KB is a small molecule drug that targets the mechanism of action of the drug. Used for Phase 2 clinical trials for KB are ongoing, but the specific indication is not publicly disclosed..","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}